$1.54
Insights on C4 Therapeutics, Inc
Revenue is up for the last 2 quarters, 2.66M → 11.07M (in $), with an average increase of 75.9% per quarter
Netprofit is up for the last 2 quarters, -35.92M → -27.03M (in $), with an average increase of 32.9% per quarter
In the last 1 year, Seagen, Inc. has given 73.8% return, outperforming this stock by 155.1%
In the last 3 years, Novo Nordisk A/s has given 18.7% return, outperforming this stock by 114.0%
1.3%
Downside
Day's Volatility :7.03%
Upside
5.81%
20.13%
Downside
52 Weeks Volatility :86.93%
Upside
83.63%
Period | C4 Therapeutics, Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -40.07% | -1.3% | 0.0% |
6 Months | -53.22% | 1.2% | 0.0% |
1 Year | -80.68% | -5.7% | -6.5% |
3 Years | -95.29% | 17.1% | -6.5% |
Market Capitalization | 73.9M |
Book Value | $4.39 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -2.75 |
Wall Street Target Price | 16.3 |
Profit Margin | 0.0% |
Operating Margin TTM | -251.16% |
Return On Assets TTM | -22.01% |
Return On Equity TTM | -50.51% |
Revenue TTM | 20.3M |
Revenue Per Share TTM | 0.42 |
Quarterly Revenue Growth YOY | 63.9% |
Gross Profit TTM | -86.7M |
EBITDA | -137.9M |
Diluted Eps TTM | -2.75 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.57 |
EPS Estimate Next Year | -2.51 |
EPS Estimate Current Quarter | -0.66 |
EPS Estimate Next Quarter | -0.61 |
What analysts predicted
Upside of 958.44%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 19.4M | - |
Net Income | -15.7M | - |
Net Profit Margin | -81.14% | - |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 21.4M | ↑ 10.42% |
Net Income | -34.1M | ↑ 117.04% |
Net Profit Margin | -159.48% | ↓ 78.34% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 33.2M | ↑ 55.25% |
Net Income | -66.3M | ↑ 94.54% |
Net Profit Margin | -199.83% | ↓ 40.35% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 45.8M | ↑ 37.93% |
Net Income | -86.0M | ↑ 29.7% |
Net Profit Margin | -187.92% | ↑ 11.91% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 31.1M | ↓ 32.08% |
Net Income | -126.5M | ↑ 47.03% |
Net Profit Margin | -406.8% | ↓ 218.88% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 13.8M | ↑ 80.74% |
Net Income | -27.4M | ↓ 13.9% |
Net Profit Margin | -198.35% | ↑ 218.05% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 6.8M | ↓ 51.18% |
Net Income | -31.4M | ↑ 14.53% |
Net Profit Margin | -465.32% | ↓ 266.97% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 2.9M | ↓ 57.74% |
Net Income | -36.1M | ↑ 14.79% |
Net Profit Margin | -1.3K% | ↓ 798.77% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 3.8M | ↑ 31.71% |
Net Income | -33.9M | ↓ 5.93% |
Net Profit Margin | -902.85% | ↑ 361.24% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.7M | ↓ 29.13% |
Net Income | -35.9M | ↑ 5.85% |
Net Profit Margin | -1.3K% | ↓ 445.57% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 11.1M | ↑ 315.62% |
Net Income | -27.0M | ↓ 24.73% |
Net Profit Margin | -244.19% | ↑ 1104.23% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 146.5M | - |
Total Liabilities | 226.2M | - |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 118.3M | ↓ 19.27% |
Total Liabilities | 230.2M | ↑ 1.76% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 400.1M | ↑ 238.35% |
Total Liabilities | 119.3M | ↓ 48.16% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 506.8M | ↑ 26.65% |
Total Liabilities | 117.2M | ↓ 1.83% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 430.8M | ↓ 14.98% |
Total Liabilities | 141.6M | ↑ 20.87% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 492.5M | ↓ 4.46% |
Total Liabilities | 147.9M | ↓ 2.04% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 461.4M | ↓ 6.3% |
Total Liabilities | 143.3M | ↓ 3.13% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 430.8M | ↓ 6.63% |
Total Liabilities | 141.6M | ↓ 1.15% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 396.0M | ↓ 8.08% |
Total Liabilities | 133.6M | ↓ 5.68% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 375.0M | ↓ 5.31% |
Total Liabilities | 141.3M | ↑ 5.79% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 333.0M | ↓ 11.2% |
Total Liabilities | 117.0M | ↓ 17.21% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -17.0M | - |
Investing Cash Flow | 36.9M | - |
Financing Cash Flow | 2.0M | - |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 55.6M | ↓ 427.51% |
Investing Cash Flow | -1.6M | ↓ 104.39% |
Financing Cash Flow | 244.0K | ↓ 87.56% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -67.2M | ↓ 220.92% |
Investing Cash Flow | -190.5M | ↑ 11659.57% |
Financing Cash Flow | 348.9M | ↑ 142904.92% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -87.0M | ↑ 29.32% |
Investing Cash Flow | -189.3M | ↓ 0.61% |
Financing Cash Flow | 171.4M | ↓ 50.88% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -105.9M | ↑ 21.82% |
Investing Cash Flow | 58.4M | ↓ 130.86% |
Financing Cash Flow | 1.1M | ↓ 99.33% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -22.2M | ↓ 16.55% |
Investing Cash Flow | 33.2M | ↓ 929.87% |
Financing Cash Flow | 259.0K | ↓ 46.04% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -28.0M | ↑ 26.24% |
Investing Cash Flow | 19.9M | ↓ 40.07% |
Financing Cash Flow | 361.0K | ↑ 39.38% |
Sell
Neutral
Buy
C4 Therapeutics, Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() C4 Therapeutics, Inc | -11.6% | -53.22% | -80.68% | -95.29% | -93.72% |
![]() Moderna, Inc. | 10.77% | -38.07% | -54.62% | -47.66% | 329.19% |
![]() Regeneron Pharmaceuticals, Inc. | -2.11% | 8.61% | 7.86% | 65.47% | 118.58% |
![]() Novo Nordisk A/s | -0.67% | 27.21% | 58.01% | 196.12% | 339.58% |
![]() Seagen, Inc. | -0.71% | 8.98% | 75.48% | 18.69% | 248.26% |
![]() Vertex Pharmaceuticals Incorporated | -8.97% | 5.01% | 10.57% | 53.8% | 97.36% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() C4 Therapeutics, Inc | NA | NA | NA | -2.57 | -0.51 | -0.22 | 0.0 | 4.39 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -11.52 | -0.22 | -0.07 | 0.0 | 35.32 |
![]() Regeneron Pharmaceuticals, Inc. | 22.78 | 22.78 | 9.01 | 42.5 | 0.17 | 0.09 | 0.01 | 234.47 |
![]() Novo Nordisk A/s | 43.04 | 43.04 | 2.03 | 2.62 | 0.89 | 0.22 | 0.01 | 20.77 |
![]() Seagen, Inc. | NA | NA | 18.53 | -4.16 | -0.28 | -0.13 | 0.03 | 13.52 |
![]() Vertex Pharmaceuticals Incorporated | 26.52 | 26.52 | 0.41 | 15.04 | 0.23 | 0.14 | 0.02 | 64.05 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() C4 Therapeutics, Inc | Buy | $73.9M | -93.72% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $29.6B | 329.19% | 24.73 | -38.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $87.0B | 118.58% | 22.78 | 30.47% |
![]() Novo Nordisk A/s | Buy | $470.4B | 339.58% | 43.04 | 35.11% |
![]() Seagen, Inc. | Hold | $40.0B | 248.26% | NA | -32.61% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $91.0B | 97.36% | 26.52 | 35.94% |
Wasatch Advisors Inc.
Soleus Capital Management, L.P.
ArrowMark Colorado Holdings, LLC (ArrowMark Partners)
T. Rowe Price Associates, Inc.
BlackRock Inc
Aquilo Capital Management, LLC
C4 Therapeutics, Inc’s price-to-earnings ratio stands at None
Read Morec4 therapeutics is an early stage drug discovery company whose mission is to harness targeted protein degradation to develop therapeutics for a broad range of diseases. the centerpiece of our approach is the degronimid® platform, which enables highly selective small molecule binders to target disease causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system.
Organization | C4 Therapeutics, Inc |
Employees | 146 |
CEO | Mr. Andrew J. Hirsch |
Industry | Health Technology |
Asymmetric Smart Alpha S&p 500 Etf
$1.54
-3.75%
Advisorshares Alpha Dna Equity Sentiment Etf
$1.54
-3.75%
Liberty Tripadvisor Hdg-b
$1.54
-3.75%
Tempo Automation Holdings Inc
$1.54
-3.75%
Falcon's Beyond Global Inc
$1.54
-3.75%
Jaguar Global Growth Corporation I
$1.54
-3.75%
Missfresh Ltd
$1.54
-3.75%
Shuaa Partners Acquisition Corp I
$1.54
-3.75%
Rose Hill Acquisition Corp
$1.54
-3.75%